SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of February 2019
Commission File Number: 333-219066
Clementia Pharmaceuticals Inc.
(Translation of registrant's name into English)
1000 de la Gauchetiere Street West, Suite 1200
Montreal, Quebec, CANADA , H3B 4W5
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
The information contained in this Report (including the exhibits hereto) is hereby incorporated by reference into Clementia Pharmaceuticals Inc.’s Registration Statement on Form F-3 (File No. 333-227726).
On February 28, 2019, the Registrant provided a Notice of its Annual General Meeting which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c) Exhibit 99.1. Notice of Annual General Meeting dated February 28, 2019.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Clementia Pharmaceuticals Inc.|
|Date: February 28, 2019|
|/s/ Steve Forte|
|Chief Financial Officer|
|1500 Robert-Bourassa Blvd.,|
|February 27, 2019||7th Floor|
|Montreal QC, H3A 3S8|
To: All Canadian Securities Regulatory Authorities
Subject: Clementia Pharmaceuticals Inc.
We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer:
|Meeting Type :||Special Meeting|
|Record Date for Notice of Meeting :||March 08, 2019|
|Record Date for Voting (if applicable) :||March 08, 2019|
|Beneficial Ownership Determination Date :||March 08, 2019|
|Meeting Date :||April 09, 2019|
|Meeting Location (if available) :||Montreal, Qc|
|Issuer sending proxy related materials directly to NOBO:||No|
|Issuer paying for delivery to OBO:||Yes|
|Notice and Access (NAA) Requirements:|
NAA for Beneficial Holders
NAA for Registered Holders
|Voting Security Details:|
Agent for Clementia Pharmaceuticals Inc.